文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

作者信息

Seymour John F, Marcus Robert, Davies Andrew, Gallop-Evans Eve, Grigg Andrew, Haynes Andrew, Herold Michael, Illmer Thomas, Nilsson-Ehle Herman, Sökler Martin, Dünzinger Ulrich, Nielsen Tina, Launonen Aino, Hiddemann Wolfgang

机构信息

Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, NSW, Australia.

Kings College Hospital, London, UK.

出版信息

Haematologica. 2020 May;105(5):1465. doi: 10.3324/haematol.2020.246991.

DOI:10.3324/haematol.2020.246991
PMID:32358081
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7193496/
Abstract
摘要

相似文献

[1]
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Haematologica. 2020-5

[2]
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Haematologica. 2018-12-20

[3]
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

Lancet Haematol. 2019-8

[4]
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.

Int J Hematol. 2018-11

[5]
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.

Pharmacoeconomics. 2019-8

[6]
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol. 2015-10-20

[7]
Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.

Leuk Lymphoma. 2019-1-11

[8]
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.

J Med Econ. 2018-10

[9]
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.

Target Oncol. 2017-4

[10]
Obinutuzumab in follicular lymphoma.

Drugs Today (Barc). 2016-12

引用本文的文献

[1]
Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas.

Ann Hematol. 2025-3

[2]
Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.

Front Immunol. 2024

[3]
Current trends in diagnosis and management of follicular lymphoma.

Am J Blood Res. 2022-8-15

[4]
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP.

EJHaem. 2020-7-31

[5]
Novel prognostic tools that identify high-risk follicular lymphoma.

Hemasphere. 2019-6-30

[6]
Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival.

Blood Adv. 2021-3-23

[7]
Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis.

Cancers (Basel). 2021-2-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索